P Sevelda|H Salzer - JoVE Visualize

Showing results (21-30 of 199) with videos related to

Pageof 20

Sort By:

Acta Obstetricia Et Gynecologica Scandinavica|April 1, 1993

Prognostic factors related to recurrent endometrial carcinoma following initial surgeryN Vavra, U Denison, H Kucera, et al.

Geburtshilfe Und Frauenheilkunde|March 1, 1987

[Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II]P Sevelda, E Gitsch, C Dittrich, et al.

Wiener Klinische Wochenschrift|August 3, 1990

[The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma]P Sevelda, M Barrada, N Vavra, et al.

International Journal of Oncology|October 17, 1998

Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatinA Obermair, P Speiser, M Thoma, et al.

Geburtshilfe Und Frauenheilkunde|May 1, 1991

[Ferritin level in newborn infants after prepartal iron medication]M Barrada, N Pateisky, C Schatten, et al.

Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997

[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993

Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.

Cancer Letters|April 30, 1990

Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.

European Journal of Cancer (Oxford, England : 1990)|May 9, 2003

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.

Wiener Klinische Wochenschrift|January 1, 1993

[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]P Sevelda, C Kurz, A Obermair, et al.

Pageof 20

Showing results (21-30 of 199) with videos related to

Sort By:

Pageof 20

Acta Obstetricia Et Gynecologica Scandinavica|April 1, 1993

Prognostic factors related to recurrent endometrial carcinoma following initial surgeryN Vavra, U Denison, H Kucera, et al.

Geburtshilfe Und Frauenheilkunde|March 1, 1987

[Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II]P Sevelda, E Gitsch, C Dittrich, et al.

Wiener Klinische Wochenschrift|August 3, 1990

[The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma]P Sevelda, M Barrada, N Vavra, et al.

International Journal of Oncology|October 17, 1998

Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatinA Obermair, P Speiser, M Thoma, et al.

Geburtshilfe Und Frauenheilkunde|May 1, 1991

[Ferritin level in newborn infants after prepartal iron medication]M Barrada, N Pateisky, C Schatten, et al.

Gynakologisch-Geburtshilfliche Rundschau|January 1, 1997

[Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods]G Knappitsch, K Gruböck, H Salzer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993

Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patientsC Dittrich, M Baur, N Vavra, et al.

Cancer Letters|April 30, 1990

Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patientsC Dittrich, E Dittrich, F Wrba, et al.

European Journal of Cancer (Oxford, England : 1990)|May 9, 2003

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatinCh Dittrich, P Sevelda, H Salzer, et al.

Wiener Klinische Wochenschrift|January 1, 1993

[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]P Sevelda, C Kurz, A Obermair, et al.

Pageof 20